

【Therapeutic category】 625 Anti-virus agents
【Non-proprietary name】 Rilpivirine hydrochloride
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving rifampicin, carbamazepine, phenobarbital, phenytoin, phenytoin/phenobarbital, fosphenytoin, apalutamide, enzalutamide, dexamethasone (systemic administration) (excluding single administration), food containing St. John's Wort, and proton pump inhibitors (omeprazole, lansoprazole, aspirin/lansoprazole, rabeprazole, esomeprazole, vonoprazan fumarate, aspirin/vonoprazan fumarate)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving rifampicin, carbamazepine, phenobarbital, phenytoin, phenytoin/phenobarbital, fosphenytoin, apalutamide, enzalutamide, <u>ivosidenib, encorafenib, mitotane</u> , dexamethasone (systemic administration) (excluding single administration), food containing St. John's Wort, and proton pump inhibitors (omeprazole, lansoprazole, aspirin/lansoprazole, rabeprazole, esomeprazole, vonoprazan fumarate, aspirin/vonoprazan fumarate)		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Apalutamide Enzalutamide	The blood concentration of this drug may decrease, leading to a reduction in the effects of this drug.	The CYP3A-inducing activity of these drugs promotes the metabolism of this drug.	Apalutamide Enzalutamide <u>Ivosidenib</u> <u>Encorafenib</u> <u>Mitotane</u>	The blood concentration of this drug may decrease, leading to a reduction in the effects of this drug.	The CYP3A-inducing activity of these drugs promotes the metabolism of this drug.
-----------------------------	--	--	---	--	--

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.